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Abstract
Introduction: Taking into account important role of apoptosis in COPD pathogenesis, we wanted to asses the serum levels of 
markers involved in apoptosis regulation, including apoptosis inducers such as TNF-a, sFasL or p53 protein and apoptosis inhibitor 
bcl-2 and, in addition, to compare these markers with selected COPD parameters.
Material and methods: In 181 patients (60 women) with COPD (age was 62.2+ 9.37 years; FEV1% 55.2 + 19.98 %) and in 29 
controls (11 women), serum levels of TNF-a, sFasL, p53 and bcl-2 were evaluated by the enzyme-linked immunosorbent assay 
(ELISA) method.
Results: In COPD patients the mean sFasL level was 0.092 ± 0.077 ng/ml and mean TNF-a level was 2.911 ± 3.239 pg/ml. There 
were no differences in serum sFasL and TNF-a in COPD patients and control group. TNF-a and sFasL did not correlate with COPD 
parameters such as FEV1%, BMI, RV% (percentage of predicted value of residual volume) or BODE. Although we tried to evaluate 
bcl-2 and p53 protein serum levels with two different tests, measurable levels of bcl-2 were only detected in 15 patients and p53 
in only 3 patients. Bcl-2 values were from 0.418 to 11.423 ng/ml and p53 from 90.772 to 994.749 pg/ml. 
Conclusions: We didn’t observe any differences in serum levels of pro- and antiapoptotic markers in COPD patients and the 
control group or correlations between the markers studied and COPD parameters. 
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Introduction
The role of apoptosis in the pathogenesis 
of COPD is complicated and still remains un-
derexplained, which is why many aspects of 
this process form the main topic of most recent 
studies.
The majority of studies concentrate on apo-
ptosis of structural cells. Segura-Valdez et al. 
presented that first of all endothelial cells from 
capillaries and arterioles exhibited patterns of 
apoptosis. Less frequently these authors also 
revealed apoptotic alveolar epithelial cells, in-
terstitial and inflammatory cells in lung tissue of 
COPD patients [1]. Other authors proved markers 
of apoptosis, including caspase-3, Bax and Bad 
in emphysematous lungs [2]. Hodge et al., after 
assessing cells obtained from bronchial brushing 
and bronchoalveolar lavage revealed increased 
apoptosis in former and current smokers with 
COPD compared to the non-smoking control gro-
ups [3]. Some authors indicated that deregulation 
of granulocyte apoptosis could lead to sustained 
inflammation [4]. The most recent studies concen-
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trate on the importance of apoptosis outside the 
lungs. Increased apoptosis of the skeletal muscle 
is responsible for the skeletal muscle atrophy [5]. 
Moreover apoptosis interacts with other pathome-
chanisms involved in the development of COPD 
such as proteinase-antiproteinase imbalance, 
inflammation and oxidative stress [6].
One of the major pathways involved in the 
regulation of programmed cell death is death 
receptor ligation. Apoptosis can be activated in 
response to extracellular signals and is mediated 
by binding members of the tumor necrosis factor 
family (e.g. Fas Ligand and TNF-a) to death recep-
tors on the cell surface [6].
The P53 tumor suppressor gene and its 
product p53 protein possess many biological 
functions, one of them is the ability to induce 
apoptosis in response to cellular stress such as 
DNA damage, hypoxia or oncogene activation. 
P53 stimulates a wide network of signals that 
act through two major apoptotic pathways. The 
activation of extrinsic apoptotic pathway by p53 
can be performed through the induction of genes 
encoding transmembrane proteins. One of these 
proteins is the cell-surface receptor Fas. P53 could 
also induce Fas mRNA expression [7, 8].
The apoptosis inhibitor bcl-2 prevents mito-
chondrial permeability transition pore opening 
and the release of apoptogenic proteins from 
mitochondria. On the one hand, bcl-2 may also 
block the p53-mediated apoptosis [9, 10] and, on 
the other hand, protein p53 plays a critical role in 
regulating of Bcl-2 family proteins [11].
The importance of the Fas/FasL system in 
the regulation of apoptosis is well known. The 
Fas transmembrane receptor is one of the death 
receptors and belongs to the TNF superfamily. 
The Fas receptor is activated by binding to its 
Fas ligand [11].
Taking into account the important role of 
apoptosis in COPD pathogenesis, we wanted 
to test the hypothesis that the development of 
COPD could be associated with alterations in 
serum levels of markers involved in apoptosis 
regulation, including apoptosis inducers such as 
TNF-a, sFasL or p53 and apoptosis inhibitor bcl-2.
Material and methods
Patients
A total of 181 patients with COPD were 
enrolled in the study. The group examined com-
prised 121males and 60 females. All patients 
were in stable disease (no during exacerbation). 
The mean age was 62.2 ± 9.37 years. COPD was 
diagnosed on the basis of the Global Initiative 
for Chronic Obstructive Lung Disease criteria. 
Mean FEV1% was 55.20% ± 19.98. The majority 
of subjects were overweight and obese with mean 
BMI 29.16 ± 7.37. 17 patients were in stage IV, 
57 in stage III, 88 in stage II and 19 in stage I of 
COPD. Almost all patients were current or former 
smokers.
COPD patients had many concomitant dise-
ases: 140 had hypertension, 40 diabetes, 30 sta-
ble ischemic heart disease and 2 had a previous 
stroke history. All patients with co-morbidities 
received standard treatment according to inter-
national recommendations In majority of cases 
hypertension was treated with ACE-inhibitors, 
usually in combination with drugs from other 
groups as diuretics or calcium blockers. Diabetes 
treatment constituted in almost all patients oral 
hypoglycemic agents. Only one patient received 
insulin treatment.
A control group constituted 29 healthy sub-
jects, including 11 females. Mean age was 49.48 
± 13.68 and mean BMI 29.56 ± 3.81.
Measurement of serum levels: TNF-a, 
sFasL, p53 and bcl-2
Blood samples were collected from fasting 
subjects in the morning. After centrifugation for 
10 minutes at 1467 RCF, the serum was removed 
and stored at −80oC. The serum levels of the 
markers assessed were measured using the enzy-
me-linked immunosorbent assay (ELISA) method. 
The following ELISA kits were used: 
 — for TNF-a: Human TNF-a Quarantikine 
High Sensitivity Kit- R&D Systems. Mini-
mum detectable dose (MDD) ranged from 
0.038−0.191 pg/ml, mean MDD 0.106 pg/ml.
 — for p53 protein two different kits were used: 
Human p53 Platinum ELISA eBioscience (the 
limit of detection 0.33 U/ml) and p53 pan 
ELISA ROCHE (the lower limit of detection 
is 9 pg/ml). 
 — for bcl-2 protein two different kits were used: 
Human bcl-2 Platinum ELISA eBioscience 
and Human bcl-2 ELISA Biovendor (limit of 
detection is 0.5 ng/ml).
 — for sFasL protein two different kits were used: 
sFasL Platinum ELISA eBioscience (the limit 
of detection 0.07 ng/ml) and Human sFasL 
R&D Systems (MDD ranged from 1.01−8.05 
pg/ml, mean MDD was 2.66 pg/ml).
The tests were performed according to the 
manufacturer’s specifications. We used the ELISA 
microplate reader from MRXe Dynex Technolo-
gies.
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Statistical analysis
Statistical analysis was performed using the 
CSS Statistica software for Windows (version 5.0). 
Spearman’s test was used to assess the relation-
ship between two variables and the Mann-Whit-
ney U test to compare values between two groups.
Differences between samples were conside-
red significant at p < 0.05. 
The work has been approved by the ap-
propriate ethical committee related to the insti-
tutions (The Bioethical Committee in Warsaw). 
The study was a part of the grant from The 
National Centre for Research and Development: 
“Chronic obstructive pulmonary disease (COPD)
-systemic disease, the biggest threat of XXI cen-
tury (No. 13003406/2009)
Results
In COPD patients, the mean sFasL level was 
0.092 ng/ml ± 0.077. We didn’t observe differen-
ces in sFasL levels between COPD patients and 
the control group (p = 0.956). The mean values of 
sFasL in the different stages of COPD are shown 
in Table 1. We didn’t demonstrate any correlations 
between sFasL serum levels and selected parame-
ters as BMI, BODE, FEV1 or RV% (Table 2). 
In COPD patients, the mean TNF-a level was 
2.911 ± 3.239 pg/ml. We didn’t find differences 
between TNF-a levels in COPD patients and the 
control group (p = 0.391). We observed that the 
average TNF concentration increased with the 
severity of the COPD, however the differences 
did not reach statistical significant levels (p = 
0.288) (Table 1). We also didn’t observe correla-
tions between TNF-a serum levels and selected 
parameters (Table 2). 
Moreover we didn’t find differences in sFasL 
(p = 0.620) and in TNFalpha levels (p = 0.547) 
between both genders.
Although we tried to evaluate bcl-2 serum 
levels with two different tests, measurable levels 
were only detected in 15 patients. The values 
ranged from 0.418 to 11.423 ng/ml. It was a very 
heterogonous group of patients. Percentage of 
FEV1 predicted value (FEV1%) ranged in these 
patients from 25% to76% and BMI from 18.6 
to 44.8. 
Similar to bcl-2, two tests were used for the 
p53 measurement. We only detected p53 protein 
in 3 serum samples, all of which were from fe-
males. The range of values was 90.772−994.749 
pg/ml. Two of the three 3 patients had low BMIs: 
16.7 and 18.6, low FEV1% 35 and 37% and 3−4 
exacerbations every year in their medical history. 
The third patient had higher FEV1% —74%, BMI 
20,2 and 1 exacerbation per year. 
Discussion
As mentioned in the introduction, the majori-
ty of studies concentrate on examining the role of 
apoptosis on cells or tissue. In the lung tissue of 
COPD smokers and non-COPD smokers, Siganaki 
et al. examined apoptosis markers in lung tissue 
using the western blot and immunochemistry. 
These authors proved increased p53 expression 
in type II pneumocytes in COPD patients, but 
there were no differences in p53 expression in 
alveolar macrophages and in lymphocyte-like 
cells. However, expression of bcl2 didn’t differ 
between the groups studied. This imbalance be-
tween pro-apoptotic p53 and anti-apoptotic bcl2 
in type II pneumocytes may indicate enhanced 
apoptosis in the alveolar epithelium of COPD 
patients [12]. 
We only detected p53 protein in serum sam-
ples from 3 females. Among them 2 of the 3 
patients were underweight , had low FEV1% and 
many exacerbations per year. This could sugge-
Table 1. TNF alpha and sFasL serum levels in the groups examined
COPD I n = 19 COPD II n = 88 COPD III n = 57 COPD IV n = 17 All COPD pa-
tients
Control p
TNF alpha pg/ml 2.474 ± 2.87 2.529 ± 1.55 3.23 +3.42 4.44 ± 7.14 2.911 ± 3.23 2.550 ± 1.48 NS
sFasL ng/ml 0.090 ± 0.08 0.098 ± 0.08 0.080 ± 0.06 0.084 ± 0.06 0.092 ± 0.07 0.071 ± 0.02 NS
Table 2. Correlation coefficients between sFasL and TNF 
alpha serum levels and selected parameters
sFasL TNF alpha
rs p rs p
BMI 0.106 NS 0.121 NS
BODE −0.034 NS 0.108 NS
FEV1% 0.036 NS −0.056 NS
RV% 0.067 NS 0.305 NS
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sts that the serum p53 level may also be helpful 
in better understanding of the role of apoptosis 
in pathogenesis of COPD progression, however 
this group was too small for any conclusions to 
be drawn. We realize that p53 is an intracellular 
protein and it’s in sera evaluation of non neopla-
smatic subjects could be disputable. However, a 
few studies indicate its importance in different 
non-neoplasmatic disorders, including COPD. 
Targowski et al. compared p53 concentrations in 
3 groups: patients with non small cell lung cancer, 
COPD and control group [13]. In this study p53 
concentration was measured using ELISA method 
and the same ROCHE test as in our study. These 
authors demonstrated increased serum concen-
tration of p53 protein in 34% of patients with 
moderate and severe COPD (without any data 
about comorbidites). Moreover, they observed a 
higher prevalence of p53 protein in the serum of 
COPD patients compared with healthy subjects 
[13]. Dincer et al. demonstrated that p53 serum 
levels were higher in acute myocardial infarction 
patients compared to the control group. These au-
thors also observed a time-dependent decrease in 
p53 levels. Such a relationship could suggest, that 
p53 may be a marker of apoptosis after myocardial 
infarction [14]. In addition, it was demonstrated 
that expression of proapoptotic genes including 
p53 was higher in unstable than in stable athero-
sclerotic plaques [15]. These findings in ischemic 
heart disease could suggest that apoptosis process 
may increase in COPD exacerbation comparing 
with stable disease. Unfortunately we were not 
able to test this hypothesis in our study, because 
all patients examined were in stable disease, but 
two of 3 patients with detected p53 had many 
exacerbations in medical history.
Rumora et al. analyzed the expression of 
Bcl-2 and Bax in the leucocytes using the we-
stern blotting. These authors demonstrated that 
expression of Bcl-2 was significantly decreased, 
especially in COPD smokers, but also in COPD 
ex-smokers and healthy smokers as compared 
with healthy non-smokers [16]. According to our 
knowledge, bcl-2 serum levels were not evaluated 
in COPD patients. Some studies showed differen-
ces in bcl-2 serum levels in lung cancer as well 
as in non-neoplasmatic diseases, which suggest 
its important role in the pathogenesis of many di-
sorders. It has been shown that in the majority of 
patients with advanced lung cancer (even in 96%) 
bcl-2 serum levels were increased and bcl-2 levels 
were higher in lung cancer subjects than in the 
control group [17]. In addition, lupus nephritis 
was associated with glomerular expression and 
increased serum levels of bcl-2, which suggests 
its role in glomerular injury [18]. In addition, pa-
tients with multiple sclerosis in the active phase 
had higher bcl-2 levels than the control group or 
patients in the inactive phase [19]. 
The interpretation of TNF-alpha serum levels 
in the examined group is much more complicated. 
TNF-alpha, originally described as a factor produ-
ced by the endotoxin stimulated macrophages, is 
now one of the most extensively studied cytoki-
nes. TNF-alpha is not only one of the apoptosis 
mediators, but it is also a powerful proinflamma-
tory cytokine [20]. TNF-alpha was often examined 
in COPD. Some studies suggest that this cytokine 
is involved in the development of cachexia in 
COPD patients [21]. Some authors also indicate a 
difference between local and systemic TNF-alpha 
production. It has been shown, that the sputum 
cells of patients with COPD produced less TNF
-alpha than the control group and this could lead 
to impaired local defense. However, these authors 
didn’t observe differences in TNF-alpha produc-
tion by blood cells between the COPD group and 
the control group [22]. Some studies suggest that 
serum TNF-alpha could correlate with steroid use 
and FEV1% [23]. This could be in accordance with 
our results indicating for higher TNF levels to be 
achieved by patients with more advanced COPD.
We didn’t find any changes in sFasL levels 
between COPD patients and the control group or 
in the different COPD stages: similar observations 
were described by other authors. Takabatake et 
al. didn’t find any differences in serum levels of 
sFasL or plasma levels of sFas. These authors didn’t 
observed any correlations between sFasL or sFas le-
vels and clinical variables in COPD patients either 
[24]. Yasuda et al. demonstrated that plasma sFas 
levels increased in severe COPD, however these 
authors didn’t observe changes in sFasL levels be-
tween COPD patients and the control group [25].
We are aware, that our study has several limi-
tations. First of all, group examined and control 
group were not good matched especially in age, 
what could have influence on TNF-alpha analysis. 
It is well known that TNF-alpha levels increase 
with age [26]. In addition many COPD patients 
were with concomitant diseases. This could also 
have influence on analyzed parameters [14]. 
Conclusions
We didn’t observe differences in serum le-
vels of pro- and antiapoptotic markers in COPD 
patients and the control group or correlations be-
tween the markers studied and COPD parameters. 
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